Clare Loane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2049828/publications.pdf

Version: 2024-02-01

24 1,918 19 25
papers citations h-index g-index

28 28 2937
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Functional Specialization of the Medial Temporal Lobes in Human Recognition Memory: Dissociating Effects of Hippocampal versus Parahippocampal Damage. Cerebral Cortex, 2022, 32, 1637-1652.	1.6	6
2	Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients. Parkinsonism and Related Disorders, 2021, 87, 61-69.	1.1	2
3	Pathologic tearfulness after limbic encephalitis. Neurology, 2020, 94, e1320-e1335.	1.5	12
4	Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain, 2019, 142, 2558-2571.	3.7	219
5	Hippocampal network abnormalities explain amnesia after VGKCC-Ab related autoimmune limbic encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 965-974.	0.9	32
6	InÂvivo visualization of age-related differences in the locus coeruleus. Neurobiology of Aging, 2019, 74, 101-111.	1.5	117
7	Network-wide abnormalities explain memory variability in hippocampal amnesia. ELife, 2019, 8, .	2.8	30
8	Association between precuneus volume and autobiographical memory impairment in posterior cortical atrophy: Beyond the visual syndrome. NeuroImage: Clinical, 2018, 18, 822-834.	1.4	43
9	¹¹ Câ€PE2I and ¹⁸ Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	2.2	45
10	Lateral parietal contributions to memory impairment in posterior cortical atrophy. NeuroImage: Clinical, 2018, 20, 252-259.	1.4	25
11	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	2.2	18
12	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	2.2	49
13	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	1.5	42
14	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	1.1	9
15	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	3.9	202
16	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain, 2013, 136, 400-411.	3.7	172
17	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 2013, 80, 1850-1855.	1.5	95
18	Ambient particulate matter and its potential neurological consequences. Reviews in the Neurosciences, 2013, 24, 323-35.	1.4	36

#	Article	IF	CITATIONS
19	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinson's Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	5.8	107
20	Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Scientific World Journal, The, 2011, 11, 1726-1734.	0.8	76
21	Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease, 2011, 43, 609-615.	2.1	40
22	Positron emission tomography neuroimaging in Parkinson's disease. American Journal of Translational Research (discontinued), 2011, 3, 323-41.	0.0	48
23	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	2.1	213
24	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. Science Translational Medicine, 2010, 2, 38ra46.	5.8	272